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NON-CLINICAL SAFETY IN DRUG DEVELOPMENT
LA SÉCURITÉ NON-CLINIQUE 
DANS LE DÉVELOPPEMENT DU MÉDICAMENT
Par Olivier Marcel Louis LOGET(1)
(communication présentée le 8 novembre 2007)
La sécurité non clinique et la toxicologie sont des sciences multidisciplinaires pour l’évaluation du rap-
port bénéfice/risque des candidats cliniques. Afin d’identifier le profil toxicologique de ces molécules
pouvant éventuellement être testées dans des essais cliniques, les études de toxicologie expérimen-
tale se focalisent sur leurs effets indésirables chez des espèces d’animaux de laboratoire sélection-
nées, avant de les extrapoler et de prédire les effets indésirables potentiels chez l’homme. Le dos-
sier non clinique est fortement orienté par les contraintes règlementaires globales et, par conséquent,
les études principales sont très bien définies et intégrées dans le processus de développement du médi-
cament. Cependant, afin de minimiser le taux d’attrition et d’améliorer la sélection des candidats aux
études cliniques selon des critères de sécurité, des méthodes de toxicologie moléculaire sont aussi uti-
lisées pour montrer comment les effets observés en sécurité non clinique peuvent être ou non extra-
polés à l’espèce humaine. Dans quelques cas, ces méthodes peuvent prouver que la toxicité est liée
à l’espèce. Cependant, la toxicologie moléculaire ne devrait pas être utilisée seule mais pour nous aider
à interpréter de façon raisonnée les données de la toxicologie expérimentale in vivo.
Mots-clés : sécurité non clinique, toxicologie réglementaire, développement du médicament, prédictibilité des
effets indésirables, extrapolation à l’homme.
RÉSUMÉ
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Non-clinical safety and toxicology are multidisciplinary sciences evaluating the benefit/risk ratio of
clinical candidates. To identify the toxicological profile of these new molecules for clinical studies,
experimental toxicology studies focus on their adverse effects in selected laboratory animal species,
before extrapolating the findings and predict potential adverse effects in man. As the non-clinical
safety file is based on stringent global regulatory constraints, core studies are very well defined and
integrated in the drug development process. However, in order to minimize the attrition rate and
to improve clinical candidate selection based on safety criteria, molecular toxicology methods are also
used to show whether non-clinical safety findings can or cannot be extrapolated to man. In some cases,
these methods can prove species-specific toxicity. However, molecular toxicology should not be used
on its own, but rather as a tool to help the interpretation of in vivo experimental toxicology data.
Key words: non-clinical safety, regulatory toxicology, drug development, predictability of adverse effects, extrap-
olation to human.
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INTRODUCTION
Historically toxicology and non-clinical safety were primarily
focused on the study of adverse effects of xenobiotics. Nowadays
non-clinical safety is mainly driven by global regulatory
constraints, and therefore core studies are very well defined and
integrated in the drug development process, but these studies
go beyond their historical goals up to the study of molecular bio-
logy in order to minimize the attrition rate and to improve cli-
nical candidate selection.
SAFETY TESTING AND THE REGULATORY
ENVIRONMENT : HISTORY AND TASKS OF
TOXICOLOGY
Regulatory and political aspects : Safety
Testing in a Global Regulatory Environment
Besides the scientific challenges, drug safety testing is overw-
helmingly driven by global regulatory constraints, e.g.
OECD/ICH guidelines, GLPs, national legislation, animal
welfare laws (FDA 2000, Good Laboratory Practice Standards
1999).
There is an increasing pressure from Health Authorities, espe-
cially the US-FDA as the World leader in setting the standards.
Health Authorities such as the FDA are influenced by politics
and public pressure. Guidances are issued for development of
drugs in a variety of disease areas where toxicology and non-
clinical drug safety play an increasing role.
Scientific and technical aspects
Is toxicology a Science ?
Toxicology is a multidisciplinary science for evaluation of
risk/benefit ratio. Toxicology takes methods from other sciences
such as : chemistry, pharmacology, pathology, biochemistry
and pharmacological chemistry, clinical medicine, forensic
medicine, genetics and veterinary medicine.
Toxicology is generally not considered to be a Science per se,
but applies different scientific methods to answer questions about
potential drugs raised by different scientists including clinicians.
Huge safety data packages are not best practice, where the appro-
priate, relevant and well understood, toxicology can be per-
formed (Diener 1997).
Tasks of Experimental Toxicology
Spectrum of toxicity, Extrapolation and Prediction of adverse
effects
In order to identify the toxicological profile of a compound,
experimental studies focus on detection of adverse effects in
carefully selected laboratory animal species and describing
the dose-effect relationship over a broad range of doses.
Results of these studies can be used to predict potential adverse
effects in other species, especially humans
Prediction of Safety
Non-clinical safety evaluation is used to identify safe starting
doses and subsequent dose escalation schemes in humans. To
do this, toxicity and reversibility of toxicity as well as other para-
meters (e.g. biomarkers) are monitored in target organs and
serum. Starting doses are defined with the expectation that
adverse effects should be very unlikely to occur Unfortunately,
although it can be used to reduce the risk, no tool can prove
the existence of a « negative » risk (i.e. prove the absence of
any risk).
Risk assessment : consequences and
perception
Risk vs. hazards
While predicting safety, one should also consider the acceptable
level of risk, which is largely dependent on the seriousness of
the disease and public perception and acceptance. Higher risk
levels are more easily accepted in certain diseases, like termi-
nal cancer than in attention deficit disorder.
The acceptability of a risk is very dependent on the indication
or the use of a drug. Late clinical studies allow epidemiologi-
cal demonstration of safe exposure. The acceptable numerical
risk is tremendously difficult to objectively define (is one case
out of 1,000,000 per year negligible ? is one case out of 100,000
per year tolerable?) and finally depends essentially on analyses
of quality of life (cost/benefit ; cost/utility).
Risk Assessment
Risk assessment is performed in several successive steps consis-
ting of hazard identification, hazard characterization, exposure
assessment and risk characterization.
The hazard of potential clinical candidates is primarily iden-
tified using animal-based and in vitro toxicology. The hazard is
characterized by dose-response relationships, mechanisms and
extrapolation. The exposure is assessed by the mean of plasma
(Cmax and AUC) as well as target tissue concentration ana-
lysis. The risk is finally characterized by its acceptability, the
level of safe exposure, the numerical risk and its effects on qua-
lity of life. The acceptability of a risk is very dependent on the
indication or the use of a drug (me-too pain killer vs. innova-
tive carcinoma treatment). Late clinical studies allow epide-
miological demonstration of safe exposure).
When Safety makes the Drug a Success… (rather than
efficacy)
The perception of risk and adverse effects is subjective. For
example, the information on adverse effect and warnings often
supersede the perception of a drug’s efficacy. Safety concerns
are the focus of the lay public and some patients in industria-
lized countries, especially, in « trivial » indications and for me-
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too products, where a favorable safety can mean success. Thus,
non-clinical safety profiling contributes to lead optimization by
identification of the candidate with the most favorable adverse
effects profile.
Tragedies Caused by Chemicals
More and more attention is paid to susceptibilities of newborns
and foetuses, which is illustrated by two of the most famous tra-
gedies caused by chemicals consisting of the so-called « grey syn-
drome » and phocomelia. The « grey syndrome » occurred after
accumulation of chloramphenicol in newborns due to not
fully developed kidneys which led to anaemia and circulatory
failure. The famous thalidomide tragedy is often presented as
an example to prove the necessity of using more than one spe-
cies of laboratory animals (Hansen et al.1999). This example
should be carefully used. It is true that thalidomide is extremely
teratogenic in primates (leading to phocomelia) and not tera-
togenic at all in rodents. However thalidomide is only slightly
teratogenic in a few strains of rabbits (including New Zealand
White rabbit), which is the most frequently selected non-rodent
species selected for teratogenicity studies. Even with the best
defined non-clinical safety designs. A 100 % predictability of
adverse side effects in the clinic will never be reached.
There are several examples from post-approval adverse side
effects leading to drug withdrawals. Some of them are presen-
ted in table 1.
SAFETY TESTING : INTEGRAL PART OF DRUG
DEVELOPMENT
In order to minimize the attrition rate and to improve clinical
candidate selection upon safety criteria, safety testing is inte-
grated in the drug development processes.
Clinical candidate selection
Non-Clinical Safety studies : a Research and
Development process for drug candidates
Discovery Research
During discovery research, researchers are focused on the
identification of disease. They use molecular modeling and then,
for the most promising molecules, chemical synthesis and
high throughput screening.
Even at these early stages, some animal efficacy studies as well
as early safety testing and prediction already take place.
Discovery Research : Compound Selection or Clinical Candidate
Selection (CSS)
During discovery research and compound selection steps,
pharmacological studies, analytical work on the active ingre-
dient (A.I.) production and batch planning are performed. Well
defined non-clinical safety studies also are performed, including
in silico approaches [e.g. DEREK (Deductive Estimation of Risk
from Existing Knowledge), MCASE (Multiple Computer
Automated Structure Evaluation)], bioavailability, safety (over-
dose limits and morbidity rates, potential of drug-drug inter-
actions and mutagenicity screen) and safety pharmacology
(study of side effects), as detailed in the following section.
Drug Discovery : early (Preliminary) Safety Testing
At very early stages, non-clinical safety studies are :
– distribution, metabolism and pharmacokinetics (DMPK),
– toxicology,
– safety pharmacology.
• DMPK
The aim of these studies is to prove that different species are
sufficiently exposed to the compound and to define their
metabolic profiles. These studies consist namely of the study of
metabolism and pharmacokinetics (allowing selection of the
most appropriate species) and drug-drug interactions (cyto-
chromes P-450 – « CYPs »).
• Toxicology and safety pharmacology
Historically the first toxicology studies consisted of the use of single
dose (acute) studies, which is now more and more subject to
controversies, which is why the first general toxicology studies are
now dose-range finding (DRF) and maximal tolerated dose
(MTD) studies generally performed in rats and dogs for up to 14
days. In parallel in vitro mutagenicity tests, including the famous
Ames test are performed as well as in vitro safety pharmacology
studies (for example hERG or Purkinje fiber tests). These studies
participate to the selection of clinical candidates.
Year Drug Indication/Class Causative Side Effet
1991 Enkaid Antiarrhythmic Cardivascular
1992 Temafloxacin Antibiotic Blood and Kidney
1997 Fenfumarine/Dexafluramine Diet pill
Heart valve
abnormalities
1998 Posicor (Midefranil)Duract (Bronfemic Na)
Ca-Channel Blocker
Rain relief
Lethal drug interactions
Liver damage
1999
Trovan
Raxar
Hismanal
Rotashield
Antibiotic
Antibiotic
Antihistamine
Rotavirus vaccine
Liver/Kidney damage
QT prolongation
Drug-drug interaction
Bowel Obstruction
2000
Renzulin
Propulsid
Lotonex
Type II diabetes
Heartburn
Irritative Bowel
Syndrome
Liver damage
Cardio-vascular
irregularities
Ischemic colitis
2001 PhenylpropanolamineBaychlor
OTC ingredient
Cholesterol reducing
Hemorrhagic stroke
Rhabdomyolysis
Table 1 : Examples of post-approval Adverse Side Effects and Related Drug
Withdrawals during the last decade.
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Clinical candidate characterization : studies
preparing Entry in Humans (« Phase 0 »)
After clinical candidate selection, the non-clinical safety stu-
dies consist of ADME (absorption, distribution, metabolism and
excretion), toxicology studies and safety pharmacology studies.
At this stage, other variables are investigated in parallel inclu-
ding including: dosage, formulation, preparation of first human
pharmacokinetic studies.
Toxicity Studies for Entry in Humans
Toxicity studies performed for entry into humans are Good
Laboratory Practices (GLP) compliant studies and consist of
general toxicology, genotoxicity and safety pharmacology stu-
dies (FDA 2000, Good Laboratory Practice Standards 1999)
General Toxicology
At this stage, general toxicology studies last 2 to 4-week and
are performed in rodent and non-rodent animal species. They
include toxicokinetics and recovery assessment (treatment-free
periods) and are GLP-compliant. Immunotoxicity parameters
can also eventually be included.
In addition, acute toxicology studies and local tolerance stu-
dies can be performed.
Genotoxicity (GLP-compliant)
Genotoxicity studies are also GLP-compliant and consists of at
least two in vitro tests (Ames test and mouse lymphoma test or
human chromosome aberration). An in vivo test can also be per-
formed (in vivo micronucleus test in rats or mice)
Safety Pharmacology
The so-called core battery of safety pharmacology studies
investigates central nervous system, cardiovascular and respi-
ratory effects.
DMPK (Drug Metabolism/Pharmacokinetic) Studies
(ADME)
DMPK studies investigate the exposure to the clinical candi-
date and its metabolism.
A = Absorption
The absorption is estimated by measuring blood/plasma concen-
trations during systemic exposure (time-dependent). Single dose
pharmacokinetics (per os, intravenously) are performed in
several animal species.
D = Distribution
In rodents, the distribution and retention within major organs
is estimated by whole body autoradiography. Specifically, mass
balance, quantitative whole body autoradiography (QWBA)
protein binding, red cell partitioning and brain penetration are
determined.
M = Metabolism
Major metabolic pathways are explored through in vitro and in
vivo investigations for demonstration of major metabolic simi-
larity/dissimilarity between the animal species used in toxicity
studies and humans. Metabolism is studied (stability and pat-
tern as well as metabolite identification) using in vitro studies
(microsomes and/or hepatocytes of several species), cyto-
chrome induction (metabolizing enzymes and transporters) and
in vivo metabolism.
E = Excretion
Rate and routes (most often biliary or urinary) of elimination
are also studied.
Screen of different Formulation
At this stage, different formulations and their respective bio-
availability are studies and compared.
Non-Clinical Safety Documentation
All these studies are documented and summarized in a well defi-
ned way.
Summary Level
Internal summary documents are generally issued by the inves-
tigators in order to summarize generated data : usually modu-
lar documents detailing background, potential safety-relevant
issues, margins of safety as well as an overview of results (sum-
maries of pharmacology, DMPK and toxicity studies).
Other documents also are prepared to be submitted to autho-
rities and consist of Investigators’Drug Brochure (IDB), Expert
Reports and Safety Reviews.
Study Level
In addition study reports are written (one report per study, accor-
ding to GLP). Results can also be reported in ‘Letter Reports’
Early Clinical Development : studies following
Entry in Humans : phase IIa
The overall objective following first studies performed in
human healthy volunteers is to perform the first evaluations of
efficacy of the drug in humans with the disease in phase IIa cli-
nical trials (pilot dose ranging, efficacy and safety studies).
Pharmacokinetic and metabolism studies are performed as
well. Formulation and active ingredient synthesis are further
elaborated.
At this stage, non-clinical safety studies consist of chronic toxi-
city studies (in life phase), carcinogenicity studies (in life-phase),
additional animal ADME studies and eventual mechanistic toxi-
city studies.
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Late Clinical Development : phase IIb/III
The main objective of phase IIb clinical trials is to allow definitive
dose finding and selection of minimal effective dose (MED).
Pharmacokinetic and metabolism studies are still performed.
Formulation work and active ingredient synthesis are further
elaborated to reach the final synthesis under Good
Manufacturing Practices and to continue process refinement.
At this stage, non-clinical safety studies consist of final repro-
duction toxicity studies (segments I and III), chronic toxicity
studies (completion), carcinogenicity studies (in life-phase) and
eventual mechanistic toxicity studies.
The final market image is defined. A meeting is scheduled with
FDA at the end of Phase II.
Entry into life-cycle management (EILC) : 
Full Development
The overall objective is to perform the definitive evaluations
to prove safety and efficacy of the drug in order to gain health
authority's approval.
Phase III clinical trials are performed. The market formulation
is completed.
At this stage, non-clinical safety studies consist of carcinoge-
nicity studies which are under completion.
An environmental assessment has to be prepared in order to
issue an Environmental Impact Statement (including disposi-
tion of clinical supplies, concentration of active ingredient into
environment as a result of its use, use of natural resources/energy
and ecotoxicology) and submitted to Regulatory Agencies.
After having put non-clinical safety studies in the perspective
of drug development, these studies (toxicity, DMPK and phar-
macology studies) will be more detailed.
NON-CLINICAL SAFETY TESTING
Different Toxicological Targets = Different
Study Types (figure 1)
The different toxicological targets previously discussed justify
different study types which are listed below and will be detai-
led in the next pages :
• single-dose (acute) toxicity or Dose Range Finding (DRF: sub-
acute) studies ;
• subchronic and chronic toxicity studies :
– 1-month ; 13-week ; 6-month in rodents ; 9-month in
non-rodents ;
• reproductive toxicology studies :
– pilot and definitive « Segment II » studies in 2 species,
– « segment I and III » studies ;
• mutagenicity studies ;
• carcinogenicity studies :
– pilot and main studies ; (alternative testing) ;
• special studies :
– irritation (rabbits ; dermal, subcutaneous, intravenous),
– sensitization/phototoxicity (guinea pigs),
– immunotoxicity (functional tests : T-cell subset classifi-
cation ; T-cell dependent antibody production),
– mechanistic toxicity studies (in vitro and in vivo).
Animal Species used
In order to correctly define its toxicological profile, taking into
consideration possible pharmacokinetic, metabolic and/or
physiological differences, clinical candidates have to be eva-
luated in non-clinical safety studies performed in at least two
different species including a non-rodent species. The most often
selected species are rats and dogs or those listed below:
– Rodents : rat, mouse ;
– Non-Rodents : dog, minipig, non-human primates (Cyno-
molgus monkey, marmoset, Rhesus monkey.
Figure 1 : Target organs in toxicology (NCE: New Clinical Entity).
COMMUNICATION
66 Bull. Acad. Vét. France — 2008 - Tome 161 - N°1  www.academie-veterinaire-defrance.org
Repeat-dose (Subchronic) Studies (tables 2 & 3)
Objectives
The objectives of the repeat-dose subchronic studies is to
determine target organs, to assess reversibility and sex diffe-
rences, to determine a No Observed Effect Level, to evaluate
toxicokinetics, to ensure safety in clinical trials and to take go
or no go decisions.
Design
The design consists of repeated dosing for up to 3 months (13-
weeks) in two species (rodent and non-rodent) using at least
3 dose-levels : high dose (maximum tolerated dose or MTD),
low dose (high therapeutic dose), medium dose (generally geo-
metric mean of the low and high doses), followed by a treat-
ment-free period allowing recovery assessment.
Endpoints
In these studies endpoints are clinical signs, body weight and food
consumption, toxicokinetics, clinical pathology (clinical che-
mistry, hematology) and anatomopathology (macroscopic post
mortem findings at necropsy, organ weights, histology/pathology).
Reproductive and developmental 
toxicology studies
Objectives
The objectives of reproductive and developmental toxicology
studies is to determine eventual effects on fertility, development,
teratology or new born. Potentially pregnant women cannot be
included in clinical trials as long as regulatory developmental
studies have not been performed (Collins et al.1999).
Design (figure 2)
Regulatory authorities have established guidelines and study
designs for assessing reproductive risks induced by chemicals.
The Food and Drug administration has defined three different
segments on development, fertility and general reproductive per-
formance :
– segment I : Fertility and Reproduction Function in Males and
Females,
– segment II : Developmental toxicology and Teratology,
– segment III : Perinatal and Postnatal studies.
Experimental design
Duration (interim kill ; recovery)
Dose groups/selection
Animal numbers
Frequency of dosing
Application routes
Clinical investigations
Symptomatology
Ophthalmology
Electrocardiography
Neurology
(Pharmacological investigations)
Clinical Pathology
Clinical chemistry
Hematology
Urinalysis
Toxicokinetics
Pathology Necropsy, Organ Weights ;Histopathology
Biometrical investigations
Table 2 : Integral Parts of Toxicity Studies.
Study type OECD Guideline Duration Dose Groups Animals/Group Groups Animals/Group Total No. ofanimals
Main study Recovery
Rodent
Range-finding 407 14-day 0,1,2,3,4 5m/5f 50
Subchronic Toxicity 407 28-day 0,1,2,3 10m/10f 0,1,2,3 5m/5f 110
Subchronic Toxicity 408 13-week 0,1,2,3 10m/10f 0,1,2,3 5m/5f 110
Chronic Toxicity (452) 6-month 0,1,2,3PK
20m/20f
5m/5f
0,1,2,3 5m/5f 200
Non-Rodent
Range-Finding 14-day 0,1,2,3,4 1m/1f 10
Subchronic Toxicity 28-day 0,1,2,3 4m/4f 3 2m/2f 36
Subchronic Toxicity 409 13-week 0,1,2,3 4m/4f 3 2m/2f 36
Chronic Toxicity (452) 9-month 0,1,2,3 4m/4f 0,1,2,3 2m/2f 48
Dose groups : 0 = Control, 1 = low, 2 = mid, 3 = high
Dose selection : Range of effects from a no-effect dose to one wich produces clear effects
m = males, f = females
Table 3 : Experimental Design According to OECD Guidelines.
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Endpoints-Females
In female reproductive toxicity studies, endpoints consist of :
– female fertility index,
– gestation index,
– live-born index,
– weaning index,
– sex ratio and percentage per sex,
– viability index.
Endpoints-Males
In male reproductive toxicity studies, endpoints consist of :
- evaluation of testicular spermatid numbers,
- sperm evaluation for motility, morphology and numbers of sper-
matozoids.
Genotoxicity Studies
Most of these studies are in vitro studies but there are also in vivo
studies (Brusick 1994).
In vitro
The most often used in vitro studies are the bacterial reverse
mutation test (Ames test), the mouse lymphoma mutation test
(ML/tk) and the human chromosome aberration test (HCA).
In vivo
The in vivo genotoxicity of choice is the micronucleus test
(MNT). This test was historically performed in mice but
nowadays more and more often in rats, allowing the use of ani-
mals from general toxicology studies.
Carcinogenicity studies
Objective
The objective of carcinogenicity studies is to identify a tumo-
rigenic potential in animals and to assess the relevant risk in
humans (Moolenaar 1994)
Design
Carcinogenicity studies are preceded by 90-day range-finding
studies with the same 2 rodent species (generally rat and
mouse) as those used for the main studies.
The main studies last generally 24 (up to 30) months in rats and
18 (up to 24) months in mouse or hamster. There are 3 dose-
and one control groups (high dose = MTD: minimum toxicity,
not altering the animal’s life-span, no more than 10 % decrease
in body weight gain) each comprising 50 animals per sex
(EPA 1996).
Endpoints (statistical evaluation ; photo
documentation)
In these studies, endpoints consist of body weight, food and
water consumption, clinical signs (including tumour palpation),
clinical biochemistry, haematology, (urinalysis) and gross-,
histopathology.
Alternatives for Carcinogenicity Testing
These models are undergoing international validation and
consist of initiation/promotion models in rodents, transgenic
mouse systems or neonatal rodent tumorigenicity model.
Figure 2 : Reproduction Toxicity – Scheme.
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The initiation/promotion model is traditionally a liver model
(but being adapted for multiple organs).
Currently, transgenic mouse systems are under validation (p53
+/– deficient model, Tg. AC model, Tg rasH2 model and
XPA–/– knock-out mouse model).
The actual status is that there is no single model accepted to
replace a carcinogenicity study, but these models are more used
to complement standard carcinogenicity studies.
Safety Pharmacology Studies, core Battery
The core battery of safety pharmacology studies involve the cen-
tral nervous system (Irwin test in rats), the cardiovascular system
with telemetry in a non-rodent species, most often dog and/or
monkey and electrophysiology in vitro studies : often hERG (in
vitro ; human ether a go-go related gene) or Purkinje fiber (in
vitro ; using often rabbit cells) and the respiratory system (ple-
thymsography in rats).
PREDICTABILITY OF ADVERSE EFFECTS AND
EXTRAPOLATION OF SAFETY DATA TO MAN
(table 4)
The Information Base for Assessment
Non-clinical assessments are performed in different (at least 2)
species. These assessments allow identification of target organs,
ideally of mechanisms of toxicity and time and exposure
dependent course of adverse effects and their eventual rever-
sibility.
Taking into consideration the results of non-clinical safety stu-
dies, No Observed Adverse Effect Levels (NOAEL) and/or No
Observed Effect Levels (NOEL) are defined in mg/kg and the
corresponding exposure is used to compare different species.
The results of these studies permit identification of surrogate
markers (for example clinical pathology or clinical investiga-
tions : ECG, ultrasound, NMR).
Prior knowledge on « Substance Class » effects is also an impor-
tant part of the information base to be taken into considera-
tion for assessment.
Criteria Influencing the Assessment
The safety assessment can be influenced by different criteria
including the relevance of toxicological findings, the target
organs (and their reversibility) and the safety factor (margin of
safety - MOS) depending on the NO (A) EL, on inter or intra
species differences and variability, and calculations of safety fac-
tors (based on « mg/kg/day » versus « toxicokinetic parame-
ters »).
The relevance of toxicological findings depends on the mecha-
nism of action, on the species specificity of the observed
effect(s), on the duration of therapy (on the age of patients) and
on the experience with related compounds.
EXTRAPOLATION TO HUMAN
The overall aim of non-clinical safety studies is to extrapolate
their results to humans.
Although there are arguments defending such extrapolation,
the correlations are imperfect and clinical testing remains a
necessity.
Nevertheless, effects produced in laboratory animals, when
appropriately qualified, are often relevant to humans. The expo-
sure of experimental animals to high doses is necessary to dis-
cover possible hazards to humans.
Diverging arguments are linked to the fact that there are spe-
cies differences in terms of physiology and metabolism (leading
to differences in general toxicology) as well as organotrophy (lea-
ding to differences in developmental toxicology). In addition,
from phase II and beyond, human patients are included in cli-
nical trials, whereas non-clinical safety studies are performed
with healthy animals.
Molecular methods can sometimes be a useful tool to interpret
how non-clinical safety findings may or may not be extrapo-
lated to humans. But data from such studies must be put in pers-
pective since, in some cases, these methods can uncover spe-
cies-specific toxicity. For example dioxin, which is toxic
chemical that has been shown to bind tightly to a protein in
mouse liver, causes liver tumors and testicular damage in
rodents. However, unleaded gasoline binds to a2-microglobu-
lin and induces male rat kidney tumors but EPA has accepted
that it is without carcinogenic risk for humans.
Type
Organ Toxicities
Predictability by
Recognition 
in man
Standard studies Special studies
Idiosyncrasy/Unknow
mechanism 0 (+) +++
Sensitization/Allergies + ++ +++
Functional disorders (+) + +++
Direct organ toxicities + ++ +++
Local irritation ++ +++ +++
Mutagenicity ++ ++ ?
Carcinogenicity ++ ++ ?
Teratogenicity ++ ++ +
Key : 0 = low + = occasionally
? = questionable ++=often
(+)=sometimes possible +++=definitely
Table 4 : Predictability of Adverse Effects.
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CONCLUSION : FUTURE REQUIREMENTS
AND CHALLENGES
Many experimental approaches were conceived about 50 years
ago, when the primary concerns were the lack of toxicity and
the determination of a no-effect level. Toxicological screening
was performed in few animals (drug-ethanol interaction, neu-
rotoxicity).
Alternatives consist of cytotoxicity, cultures of retina, brain and
meningeal cells, hepatocytes or kidney cells or use of molecu-
lar methods, proving some cases of species-specific toxicity as
described above.
In summary, the actual trend is to move from essentially des-
criptive activities, complemented by analytical and « measu-
ring science » used in the past to more refined models.
In the future, the aim is to reduce even further animal testing
by using improved tools, including : micro-methods for in vitro
testing, genetically modified cells and animals, toxicogenomics,
proteogenomics and metabonomics as well as in silico tools.
The usefulness of these or other refined molecular methods is
obvious. However, the danger remains that molecular toxico-
logy will be taken at face value, instead of for its predictive value.
For example, the LD50, Draize test and 12-month studies
have been abandoned and there is an ongoing debate concer-
ning carcinogenicity studies because they are no longer consi-
dered important. Notwithstanding improvements, there still
remains a tendency to overestimate the importance of mole-
cular toxicology data. Although most classical toxicology stu-
dies are still necessary, the trend is to refine studies and to reduce
the number of animal used. Thus it is not yet possible to replace
most in vivo toxicology studies with in silico and in vitro equi-
valents. Nevertheless, there has been a tremendous reduction
of numbers of animals used in non-clinical studies.
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